Citius Oncology (NASDAQ: CTOR)
$1.79
(5.9%)
$0.10
Price as of August 13, 2025, 4:00 p.m. ET
Citius Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Citius Oncology Company Info
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.